Menu
Back to Archived Journals » Research and Reports in Endocrine Disorders » Volume 5
Profile of idursulfase for the treatment of Hunter syndrome
Authors Sestito S, Ceravolo F, Grisolia M, Pascale E, Pensabene L, Concolino D
Received 20 March 2015
Accepted for publication 5 May 2015
Published 9 July 2015 Volume 2015:5 Pages 79—90
DOI https://doi.org/10.2147/RRED.S64347
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 4
Editor who approved publication: Professor Mingzhao Xing
Simona Sestito, Ferdinando Ceravolo, Michele Grisolia, Elisa Pascale, Licia Pensabene, Daniela Concolino
Department of Pediatrics, University Magna Graecia of Catanzaro, Catanzaro, Italy
Abstract: Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is a rare X-linked lysosomal storage disorder caused by deficiency of the enzyme iduronate-2-sulfatase (IDS). Enzyme replacement therapy (ERT) with recombinant human IDS, available since 2005, is currently the most appropriate treatment for this progressive, multisystemic, chronic, and life-threatening disease. Efficacy and safety of therapy with idursulfase have been assessed in several clinical trials, and confirmed in many clinical reports. Long-term follow-up of patients receiving ERT has demonstrated the importance of an early onset of treatment with idursulfase, before irreversible pathological changes occur. Intravenously administered idursulfase is not able to cross the blood–brain barrier, so neurological signs and symptoms cannot benefit from ERT, still remaining a major challenge in the treatment of MPS II.
Keywords: MPS II, glycosaminoglycans, enzyme replacement therapy, ERT
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.